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Norway
Parasympathetic withdrawal plays an important role in the autonomic dysfunctions in 
hypertension. Since hyperpolarizing, voltage-sensitive K+ channels (KV) hamper transmit-
ter release, elevated KV-activity may explain the disturbed vagal control of heart rate (HR) 
in hypertension. Here, the KV inhibitor 3,4-diaminopyridine was used to demonstrate the 
impact of KV on autonomic HR control. Cardiac output and HR were recorded by a flow 
probe on the ascending aorta in anesthetized, normotensive (WKY), and spontaneously 
hypertensive rats (SHR), and blood pressure by a femoral artery catheter. 3,4-diami-
nopyridine induced an initial bradycardia, which was greater in SHR than in WKY, 
followed by sustained tachycardia in both strains. The initial bradycardia was eliminated 
by acetylcholine synthesis inhibitor (hemicholinium-3) and nicotinic receptor antagonist/
ganglion blocker (hexamethonium), and reversed to tachycardia by muscarinic receptor 
(mAchR) antagonist (atropine). The latter was abolished by sympatho-inhibition (reser-
pine). Reserpine also eliminated the late, 3,4-diaminopyridine-induced tachycardia
in WKY, but induced a sustained atropine-sensitive bradycardia in SHR. Inhibition of 
the parasympathetic component with hemicholinium-3, hexamethonium, or atropine 
enhanced the late tachycardia in SHR, whereas hexamethonium reduced the tachycar-
dia in WKY. In conclusion, 3,4-diaminopyridine-induced acetylcholine release, and thus 
enhanced parasympathetic ganglion transmission, with subsequent mAchR activation 
and bradycardia. 3,4-diaminopyridine also activated tachycardia, initially by enhancing 
sympathetic ganglion transmission, subsequently by activation of norepinephrine release 
from sympathetic nerve terminals. The 3,4-diaminopyridine-induced parasympathetic 
activation was stronger and more sustained in SHR, demonstrating an enhanced inhib-
itory control of KV on parasympathetic ganglion transmission. This enhanced KV activity 
may explain the dysfunctional vagal HR control in SHR.
 
Keywords: hypertension, parasympathetic ganglia, sympathetic ganglia, norepinephrine release, acetylcholine 
release, heart rate, voltage-sensitive K+-channels, 3,4-diaminopyridine
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inTrODUcTiOn
It is generally accepted that hypertension is associated with sym-
pathetic hyperactivity and parasympathetic hypoactivity (1–3), 
and a high resting heart rate (HR) is the most reliable predictor 
of cardiovascular morbidity and hypertension in human (4, 5). 
Sympathetic control of HR is on a beat-to-beat basis controlled 
by the baroreflex, activated by a rise in blood pressure (BP). 
Information from the baroreceptors is mediated to the nucleus 
tractus solitarii, leading to downregulation of sympathetic 
output from the rostral ventrolateral medulla as well as to the 
stimulation of the nucleus ambiguous with subsequent activa-
tion of efferent vagal nerves to the heart. Thus, HR is controlled 
by both inhibitory parasympathetic vagal nerves and stimula-
tory sympathetic nerves. The elevated HR in hypertension may 
therefore result from an insufficient vagal inhibition of the 
sympathetic activity.
Autonomic dysregulation is also a characteristic feature of 
heart failure, manifested by increased sympathetic activity and 
reduced parasympathetic activity (6). Abnormalities in the vagal 
control of HR may be directly responsible for a poor outcome in 
myocardial infarction (7). In heart failure, there is evidence in 
animals and humans to indicate that the parasympathetic ganglia 
act as a bottleneck to efferent vagal traffic (8). It may therefore be 
hypothesized that parasympathetic ganglia are responsible for a 
dysfunctional vagal control of HR also in hypertension.
A major component of the parasympathetic control of HR 
involves inhibition of sympathetic activation, i.e., sympathetic 
activity acts as a substrate for vagal inhibition (9). Analysis of the 
sympathetic–parasympathetic interaction in the control of HR 
therefore requires both systems to be activated simultaneously. 
Dual control is not easily activated in the anesthetized rat but was 
achieved by 4-aminopyridine (4-AP) (10). 4-AP blocks voltage-
sensitive K+ channels (KV) and therefore depolarizes neurons, 
and, through that, it opens voltage-sensitive Ca2+ channels. The 
resulting entry of Ca2+ activates neuronal transmitter release. 
Similar events stimulate Ca2+-induced contraction in vascular 
smooth muscle cells (VSMCs). 4-AP-injected IV in normoten-
sive rats (WKY) therefore induced a transient rise in TPR. It 
also induced bradycardia due to release of acetylcholine (Ach) 
from parasympathetic nerves in WKY but not in spontaneously 
hypertensive rats (SHR). The initial response was in both strains 
followed by a sustained tachycardia, which was abolished by 
reserpine and was therefore due to norepinephrine (NE) release 
from peripheral sympathetic nerves (10). The nicotinic recep-
tor (nAchR) antagonist hexamethonium eliminated the initial 
4-AP-induced bradycardia in WKY and reversed the bradycardia 
to tachycardia in SHR, suggesting that the initial parasympathetic 
component resulted from activation of parasympathetic ganglion 
transmission. However, hexamethonium did not alter the late 
tachycardia in either strain, although a minor, but prolonged 
atropine sensitive, parasympathetic component was revealed 
in SHR when the sympathetic tachycardia had been eliminated 
(10). The response to 4-AP was therefore largely dominated by 
activation of NE release in SHR, making it difficult to analyze the 
mechanisms involved in the parasympathetic control of HR and 
to evaluate strain-related differences in this component.
4-Aminopyridine easily enters the central nervous system 
(CNS) (11, 12), where it may increase central sympathetic output 
by activating release of Ach (11, 13). This activation may influence 
the peripheral effects of 4-AP on parasympathetic and sympa-
thetic ganglion transmission and neuronal release. In a previous 
study (14), another KV inhibitor, i.e., 3,4-diaminopyridine (3,4-
DAP), which does not cross the blood–brain barrier (12, 15), 
was found to be more efficient than 4-AP in producing an initial 
bradycardia in SHR. It was also far more efficient in activating 
salivation (15), suggesting that it may be a better parasympathetic 
activator than 4-AP. In the present study, 3,4-DAP was therefore 
used to explore if the impact of KV on autonomic HR control in 
SHR differed from that in WKY. By use of pharmacological inter-
vention prior to 3,4-DAP as out-lined in Figure 1, two hypothesis 
were tested: (1) if the parasympathetic component involved in 
the HR response to 3,4-DAP resulted from activation of para-
sympathetic ganglion transmission, with release of Ach from the 
preganglionic neuron and activation of postsynaptic nAchR, 
leading to stimulation of muscarinic receptors (mAchRs) in 
rhythm-controlling effector cells, such as the sinoatrial node. (2) 
If augmented hyperpolarizing KV currents hampered the release 
of Ach in parasympathetic ganglia in SHR, thus precipitating the 
parasympathetic withdrawal and altered autonomic control of 
HR associated with hypertension.
MaTerials anD MeThODs
surgical Procedure
All experiments were approved by The Norwegian Animal 
Research Authority (NARA), project license no FOTS 2914, 
and were conducted in accordance with the European Directive 
2010/63/EU. The experiments included 12–14  weeks old, male 
SHR (Okamoto, SHR/NHsd strain, n  =  94, 299  ±  3  g body 
weight) and WKY (Wistar Kyoto, n = 72, 298 ± 4 g body weight) 
on conventional rat chow diet (0.7% NaCl). The rats were anes-
thetized with pentobarbital (65–75 mg/kg IP), and a satisfactory 
level of surgical anesthesia was verified by non-responsiveness to 
pinching between the toes. The rats were tracheotomized, and a 
heparinized catheter was inserted into the femoral artery for the 
measurement of systolic (SBP) and diastolic (DBP) BP and HR. 
After the starting BP and HR had been recorded, the rats were 
connected to a positive-pressure respirator and ventilated with 
air throughout the experiment. The thoracic cavity was entered 
through the third intercostal space, and a 2SB perivascular flow 
probe, connected to a T206 Ultrasonic Transit-Time Flowmeter 
(Transonic Systems Inc., Ithaca, NY, USA), was placed on the 
ascending aorta to measure cardiac output (CO, i.e., without 
cardiac flow) and from now on also HR. The thoracic cavity 
was subsequently closed with a suture. Body temperature was 
maintained at 37–38°C by external heating, guided by a thermo 
sensor carefully inserted inguinally into the abdominal cavity. 
When surgery was completed, the arterial catheter was flushed 
with 0.15  ml buffered saline (PBS; 0.01M Na-phosphate, pH 
7.4, 0.14M NaCl) containing 500  IU/ml heparin. Drugs were 
dissolved in PBS and administered as bolus injections through 
a catheter in the femoral vein (0.6–1.3 ml/kg), unless otherwise 
FigUre 1 | suggested localization of the inhibitory effect of 3,4-DaP on KV in pre- and postganglionic parasympathetic and sympathetic neurons 
involved in the regulation of hr. By inhibiting KV, 3,4-DAP will induce Ach release from preganglionic parasympathetic and sympathetic nerve endings as well as 
in postganglionic parasympathetic nerve terminals, and also induce norepinephrine (NE) release from postganglionic sympathetic nerve endings. The inhibitors used 
to localize the effect of 3,4-DAP, i.e., the Ach synthesis inhibitor hemicholinium-3, the mAchR and nAchR blockers atropine and hexamethonium, respectively, 
reserpine which depletes sympathetic nerve endings of NE, and the βAR antagonist nadolol, which block sympathetic control of HR, are indicated in capital letters 
next to site of action. When effect of one drug involved more than one step in the response chain or involved both the parasympathetic and sympathetic chains, 
drugs were combined to identify the site of 3,4-DAP action. Through the effect on HR, the results showed that Ach release from preganglionic vagal nerves was 
blunted by augmented 3,4-DAP-sensitive hyperpolarizing KV activity in SHR (indicated in upper gray box), thus preventing activation of the postganglionic neuron 
and vagal inhibition of HR (indicated in lower gray box). Presynaptic KV in the parasympathetic ganglia therefore functioned as a bottleneck in vagal transmission in 
SHR. These ganglia are likely to be located in superficial fat tissue close to the sinoatrial node. Blunted arrows indicate the inhibitory effect of presynaptic KV on 
transmitter release.
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indicated. A stabilizing period of 10 min was allowed before the 
first experimental drug was injected.
experimental Protocols
Protocol 1: The Cardiovascular Response to 3,4-DAP
Control rats were pre-treated with a sham injection containing 
vehicle (PBS) and 10  min later injected with the KV blocker 
3,4-DAP (34.5  μmol/kg) to stimulate dual activation of the 
autonomic nervous system. The cardiovascular response was 
then monitored for 25 min. To study the role of Ach release from 
preganglionic and postganglionic nerve endings as outlined in 
Figure 1, the PBS-sham injection was substituted with hemicho-
linium-3 (17.4 μmol/kg), which blocks the rate limiting step in 
Ach synthesis, i.e., re-uptake of choline through the high-affinity 
choline transporter. Hemicholinium-3 does not penetrate the 
blood–brain barrier (16). Involvement of parasympathetic/sym-
pathetic ganglion transmission was studied by pre-treatment with 
the peripherally restricted (17), non-selective nAchR antagonist/
ganglion blocker hexamethonium chloride (37 μmol/kg) (18). To 
evaluate activation of postganglionic, postsynaptic mAchR, the 
rats were pre-treated with atropine sulfate (6.9 μmol/kg, −20 min). 
As indicated in Figure 1, the impact of transmitter release from 
sympathetic nerve terminals was identified by pre-treatment with 
reserpine (8.2 μmol/kg IP, -48 and -24 h) (15), which depletes sym-
pathetic nerve endings of NE. The effect of β-adrenergic blockade 
was studied by pre-treatment with nadolol (8.5 μmol/kg 10 min 
before 3,4-DAP) (19), a β1+2AR antagonist that does not penetrate 
the blood–brain barrier. Nadolol was administered alone in both 
strains and in SHR also 10 min after injection of atropine as above. 
In addition, SHR was pre-treated with quinidine (46.2 μmol/kg) 
(20), a peripherally restricted (21), class Ia antiarrhythmic drug, 
which also blocks K+ channels, such as the 4-AP sensitive KV1.5 
(22, 23) and the muscarinic KAch (Kir3.1/Kir3.4) (24).
Protocol 2: The Cardiovascular Response to 4-AP 
Compared to 3,4-DAP
This protocol was similar to that in Protocol 1, but 3,4-DAP was 
substituted with an equimolar injection of 4-AP (34.5 μmol/kg) 
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(10, 15). To demonstrate the role of Ach release in the response 
to 4-AP, the rats were pre-treated with hemicholinium-3 as above.
Protocol 3: The Cardiovascular Response to Nicotine
The postsynaptic nAchR in parasympathetic and sympathetic 
postganglionic neurons can be stimulated directly by nicotine 
(Figure 1). To investigate if the ability of these nAchR to respond 
differed in the two strains, WKY and SHR were injected with the 
agonist nicotine (1.8 μmol/kg), and the cardiovascular response 
was monitored for 15 min. To study if 3,4-DAP modified nAchR 
function in SHR, nicotine was injected 25 min after 3,4-DAP.
3,4-DaP- and 4-aP-induced salivary Flow 
and glandular Kallikrein secretion
Salivation does not occur in anesthetized rats but can be stimu-
lated, here with 3,4-DAP or 4-AP, due to the activation of trans-
mitter release from autonomic nerves. Nicotine does not activate 
salivation. Whole saliva was collected from the oral cavity with a 
pipette throughout the 4-AP- and 3,4-DAP-observation period. 
Saliva volume was recorded by weight. Saliva was stored at −20°C 
until assayed for S2266-kallikrein-like enzyme activity as an 
indication of sympathetic activation, since submandibular gland 
kallikrein in the rat is massively released upon α1-adrenergic 
stimulation (25). In short, saliva, diluted in PBS (100 μl total), 
together with 800  μl assay buffer (0.2  mol/l Tris/HCl buffer, 
pH 9.0) were incubated up to 5 min at 37°C with 2 mM S2266 
substrate (26). The reaction was stopped with 100 μl of 50% (v/v) 
acetic acid, and absorption was measured at 405 nm.
Measurement of Plasma catecholamines
A total of 1.5 ml blood was collected at the end of the experiment 
by free flow from the femoral artery catheter into tubes containing 
45 μl 0.2M glutathione and 0.2M EGTA (4°C). Plasma was stored 
at −80°C until catecholamine concentrations were determined 
using 400 μl plasma and the 5000 Reagent kit for HPLC analysis of 
Catecholamines in plasma from Chromsystems GmbH, Munich, 
Germany, as previously described (27).
Drugs
Pentobarbital was obtained from The Norwegian National 
Hospital, Oslo, Norway; and S2266 from Kabi Diagnostica 
(Stockholm, Sweden). The remaining drugs were from Sigma 
Chemical Co., St. Louis, MO, USA.
statistical analyses
The results are presented as mean values ± SEM. The cardiovas-
cular data recorded throughout the experiments were averaged 
every minute, except during the initial response to 3,4-DAP, 4-AP, 
or nicotine, where data were averaged every seventh heartbeat. 
The cardiovascular response to pre-treatment, baselines prior to 
3,4-DAP and 4-AP, salivary flow, and the salivary kallikrein and 
plasma catecholamine concentrations were evaluated overall by 
one-way ANOVA, including all groups within each strain in each 
protocol. When the presence of group differences was indicated, 
these were located by two-tailed, two-sample Student’s t-tests for 
parametric data, and by Kruskal–Wallis tests for non-parametric 
data. The HR response to 3,4-DAP/4-AP was recorded at the initial 
TPR peak response, i.e., at about 1–1.5 min, and during the late 
response, i.e., at 10, 15, 20, and 25 min. The response to nicotine 
was recorded at the HR nadir and the TPR peak response within 
the first minute and subsequently every minute throughout the 
observation period. Since TPR is determined by the vessel radius 
in the fourth power, changes in TPR were expressed in percent 
of before values. The 3,4-DAP/4-AP/nicotine-response curves 
were analyzed using repeated measures analyses of variance 
and covariance, first as overall tests including all groups within 
each strain and each protocol, and subsequently between groups 
or for each group separately. Significant responses (two-tailed, 
one-sample Student’s t-tests) and group differences (two-tailed 
two-sample Student’s t-test or Kruskal–Wallis tests) were subse-
quently located at specific times, i.e., during the initial response 
and at the end of the experiment. Testing proceeded only when 
the presence of significant responses, differences, and/or interac-
tions was indicated. The P-value was for all tests and each step 
adjusted according to Bonferroni, except for salivary flow, the 
salivary kallikrein and plasma catecholamine concentrations, 
where P ≤ 0.05 was considered significant.
resUlTs
effect of Pre-Treatment on cardiovascular 
Baselines
MBP and HR before the rats were connected to the ventilator 
were 67 ± 4 and 143 ± 10 mm Hg and 279 ± 12 and 376 ± 9 bpm 
in the WKY and SHR controls, respectively (P  <  0.001 for 
strain-related differences). When connected to the ventilator and 
thoracotomized, BP remained not much different in WKY but 
was reduced in SHR because of a reduction in the venous return 
to the right heart due to the intrathoracic pressure. However, 
there was little change in HR. Still MBP remained higher in SHR 
than in WKY (Table 1). Also, baseline HR and TPR prior to 3,4-
DAP were higher in the SHR controls than in the WKY controls 
(P = 0.007).
Hemicholinium-3 reduced baseline MBP and TPR in WKY 
and HR in SHR (P  ≤  0.01). Hexamethonium reduced MBP, 
HR and TPR in both strains, whereas atropine had no effect. 
Reserpine and nadolol reduced HR in SHR. Quinidine reduced 
MBP and HR (P ≤ 0.007) (tested in SHR only).
The hr response to 3,4-DaP
3,4-Diaminopyridine induced an immediate bradycardia 
(P ≤ 0.002), which was greater in SHR than in WKY (P = 0.005) 
(Figure 2). Subsequently, HR increased, and a sustained tachy-
cardia was observed (P < 0.0001 at 25 min) with no significant 
strain-related difference after 25 min (Figure 2).
The Immediate HR Response to 3,4-DAP
Pre-treatment with the Ach synthesis inhibitor hemicholinium-3 
or the nAchR antagonist hexamethonium eliminated the imme-
diate HR response to 3,4-DAP in both strains (Figure 2). After 
the mAchR antagonist atropine, the initial 3,4-DAP induced 
bradycardia was reversed to tachycardia in both strains (P ≤ 0.01 
FigUre 2 | The hr response to 3,4-DaP after pre-treatment with cholinergic inhibitors or quinidine. Quinidine was given to SHR only. Significant 
responses (* within symbol) and group differences (* in brackets) at HR-nadir (after about 1 min, brackets left of curves) and at 25 min (right of curves) were located 
as indicated. *Left of symbol at 10 min in SHR indicates significant differences compared to the control group. *P < 0.0167 after curve analyses (please see Section 
“Materials and Methods” for details).
TaBle 1 | cardiovascular baselines prior to 3,4-DaP, i.e., after pre-treatment, and the response to pre-treatment below in parenthesis.
Pre-treatment WKY shr
MBP (mm hg) hr (bpm) TPr  
(mm hg/ml/min)
MBP (mm hg) hr (bpm) TPr  
(mm hg/ml/min)
PBS Vehicle  65 ± 5  
   (1 ± 1)
  301 ± 15  
 (−7 ± 5)
2.10.1  
(−0.1 ± 0.0)
  84 ± 6*  
(−5 ± 4)
   381 ± 12*  
  (−8 ± 9)
   5.2 ± 0.6*  
(−0.7 ± 0.2)
Hemicholinium-3 Ach synthesis 
inhibitor
 58 ± 4  
(−26 ± 4)†
  303 ± 16  
 (−5 ± 8)
  2.1 ± 0.1  
 (−0.5 ± 0.1)†
 60 ± 7  
(−21 ± 7)
  354 ± 14  
 (−43 ± 9)†
   3.1 ± 0.2†  
(−0.9 ± 0.3)
Hexamethonium nAchR  
antagonist
  39 ± 5†  
(−29 ± 6)†
 257 ± 12  
  (−53 ± 14)†
  1.7 ± 0.1  
 (−0.7 ± 0.2)†
  53 ± 2†  
(−33 ± 7)†
  345 ± 19  
 (−67 ± 8)†
   2.9 ± 0.2†  
(−1.5 ± 0.2)†
Atropine mAchR  
antagonist
   68 ± 10  
 (−2 ± 3)
  307 ± 15  
    (19 ± 12)
  1.7 ± 0.2  
(−0.3 ± 0.1)
 76 ± 4  
   (5 ± 7)
  374 ± 13  
(−33 ± 6)
  3.9 ± 0.3  
(−0.1 ± 0.2)
Reserpinea  
+ PBS
Depletes 
norepinephrine
 58 ± 3  
   (0 ± 0)
307 ± 4  
(−14 ± 4)
  2.0 ± 0.1  
  (0.0 ± 0.0)
 62 ± 4  
   (1 ± 2)
   309 ± 12†  
(−23 ± 5)
  4.1 ± 0.3  
   (0.4 ± 0.1)†
Reserpine  
+ atropine
 66 ± 4  
  (−7 ± 2)†
328 ± 9  
      (5 ± 12)
  1.9 ± 0.1  
(−0.3 ± 0.1)
 73 ± 6  
   (1 ± 2)
 278 ± 8†  
  (−19 ± 11)
  4.3 ± 0.4  
(−0.4 ± 0.3)
Nadolol β1+2AR  
antagonist
 61 ± 4  
   (2 ± 1)
312 ± 6  
(−10 ± 2)
  2.0 ± 0.2  
  (0.0 ± 0.1)
 69 ± 5  
(−8 ± 3)
343 ± 6  
   (−67 ± 25)†
  3.9 ± 0.3  
(−0.1 ± 0.2)
Atropine + nadolol Not done  61 ± 9  
(−9 ± 4)
  325 ± 12  
(−33 ± 6)
  3.8 ± 0.2  
(−0.0 ± 0.2)
Quinidine Antiarrhythmic  
+ KV/KAch inhibitor
Not done  67 ± 5  
(−42 ± 9)†
  313 ± 14  
   (−63 ± 13)†
   2.5 ± 0.4†  
(−1.2 ± 0.4)
aSince reserpine was administered prior to the experiment, the effect of reserpine is indicated by the differences in baselines. Comparisons were made between the WKY and SHR 
controls (*) and between the PBS control and experimental groups within each strain (†). Sixteen rats were included in the WKY and SHR controls, and 6–9 rats in the experimental 
groups.
*P ≤ 0.017.
†P ≤ 0.006.
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FigUre 3 | The hr response to 3,4-DaP after pre-treatment with reserpine or nadolol, alone or combined with atropine. Atropine + nadolol was given 
to SHR only. Significant responses (* within symbol) and group differences (* in brackets) at 1 (left of curves) and 25 min (right of curves) were located as indicated. 
Comparisons were made between the control and the experimental groups, and between the groups pre-treated with reserpine/atropine and reserpine + atropine, 
and between the nadolol- and atropine + nadolol-treated groups. *P < 0.025 after curve analyses.
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one-sample Student’s t-test, P = 0.003 compared to the controls) 
(Figure 2). As outlined in Figure 1, these results demonstrated 
that 3,4-DAP-activated Ach release from the preganlionic neuron, 
thus activating the postsynaptic nAchR in parasympathetic post-
ganglionic neuron, subsequently stimulating mAchR on rhythm-
controlling cells. Elimination of the sympathetic component by 
pre-treatment with reserpine, enhanced the immediate, 3,4-DAP-
induced bradycardia in SHR but had no effect on the bradycardia 
in WKY (Figure 3). When reserpine was combined with atropine, 
the bradycardia was eliminated in SHR (P ≤ 0.002 compared to the 
control and reserpine-only groups), showing that the bradycardia 
depended on parasympathetic activation. However, an initial 
tachycardia, as observed after atropine alone, was not observed 
(P = 0.001 compared to that after atropine alone). The same pattern 
was seen in WKY (Figure 3). This observation demonstrated that 
the initial tachycardia in atropine-treated rats was due to activa-
tion of sympathetic ganglion transmission and mediated through 
sympathetic nerves. The peripherally restricted β1+2AR antagonist 
nadolol had no significant effect on the initial 3,4-DAP-induced 
bradycardia in either strain (Figure 3). After pre-treatment with 
atropine +  nadolol, 3,4-DAP produced no initial HR response 
(tested in SHR only), similar to that seen after reserpine + atro-
pine in this strain. Pre-treatment with quinidine, similar to that 
after atropine, reversed the initial 3,4-DAP-induced bradycardia 
to tachycardia (P = 0.021) (tested in SHR only, Figure 2).
The Late HR Response to 3,4-DAP
When sympathetic nerve endings had been depleted of NE by 
reserpine (Figure  1), the 3,4-DAP-induced late tachycardia 
was abolished in WKY (P = NS) and reversed to a prominent 
bradycardia in SHR (P = 0.005 at 25 min, P < 0.001 compared 
to the controls) (Figure  3). These results showed that the late 
tachycardia depend on sympathetic nerve transmitter release in 
both strains. The reserpine-dependent bradycardia in SHR was 
eliminated by additional pre-treatment with atropine, resulting in 
a minor tachycardia, which was clearly less than that observed in 
the control or atropine-only groups (P < 0.001). These observa-
tions demonstrated that the 3,4-DAP-induced parasympathetic 
activation was present also during the late part of the observa-
tion period in SHR. The β1+2AR antagonist nadolol eliminated 
the 3,4-DAP-induced tachycardia in both strains, but, unlike 
reserpine, did not reverse the response to bradycardia in SHR 
(Figure 3). An eliminated late HR response to 3,4-DAP was also 
observed after atropine + nadolol (tested in SHR only) (Figure 3).
Blocking the ganglionic nAchR with hexamethonium 
(Figure  1) reduced the late 3,4-DAP-induced tachycardia in 
WKY, whereas a reduction was not detected in SHR (Figure 2), 
showing that the activation of sympathetic nerve transmitter 
release depended in part on activation of sympathetic ganglia in 
WKY, but not in SHR. The augmented impact of KV in parasym-
pathetic ganglia in SHR was also demonstrated by the enhanced 
development of the 3,4-DAP-induced tachycardia after pre-
treatment with hemicholinium-3, hexamethonium, or atropine, 
with an elevated ΔHR in the 10- to 20-min interval (P < 0.0001) 
(Figure  2). The same was observed after quinidine in SHR, 
although with an elevated ΔHR also after 25 min (Figure 2).
The BP and TPr response to 3,4-DaP
During the immediate response to 3,4-DAP, there was also an 
immediate rise in MBP and TPR in both strains (P <  0.0001), 
with no strain-related differences detected (Figures  4 and 5). 
Hemicholinium-3, hexamethonium, and atropine had no effect 
on the immediate TPR response to 3,4-DAP in WKY. These drugs 
increased ΔTPR in SHR, but the difference was statistically sig-
nificant for hemicholinium-3 only (Figure 4). Reserpine reduced 
the immediate TPR response to 3,4-DAP in WKY and ΔMBP 
FigUre 4 | The TPr response to 3,4-DaP after pre-treatment with cholinergic inhibitors or quinidine. The effect of quinidine was not tested in WKY. 
Significant responses (* within symbol) and group differences (* in brackets) at 1 (left of curves) and 25 min (right of curves) were located as indicated. *P < 0.025 
after curve analyses.
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in both strains (P ≤  0.005) (Figure 5), demonstrating that NE 
release contributed in part to the rise in TPR in WKY. ΔTPR was 
reduced after reserpine + atropine in SHR. The immediate TPR 
response was enhanced after pre-treatment with nadolol in WKY 
but not in SHR (Figure 5).
The vasoconstrictory TPR response to 3,4-DAP quickly 
returned to pre-injection levels in WKY, but remained high in 
SHR (P < 0.001). The elevated late response in SHR was elimi-
nated by reserpine, also in the presence of atropine (P ≤ 0.012), 
but was not influenced by nadolol (Figure 5), by atropine alone, 
hemicholinium-3, hexamethonium, or quinidine (Figure  4). 
Reserpine also reduced the MBP response throughout the 
3,4-DAP-observation period in SHR (Figure  5). These obser-
vations demonstrated that the elevated, late TPR response to 
3,4-DAP in SHR was due to activation of neuronal NE release, 
independent of ganglion transmission.
The cardiovascular response to 4-aP
4-Aminopyridine induced a minor, initial bradycardia in WKY, 
not different from that following 3,4-DAP (Figure  6). There 
was no immediate change in HR in response to 4-AP in SHR. 
The tachycardia 25 min after 4-AP and 3,4-DAP did not differ 
in either strain. Pre-treatment with hemicholinium-3 resulted 
in an immediate 4-AP-induced tachycardia (P <  0.0001), and 
also an enhanced late tachycardia (P = 0.001) in SHR, whereas 
hemicholinium-3 had no significant effect on the HR response 
to 4-AP in WKY.
The TPR response to 4-AP did not differ from that observed 
in response to 3,4-DAP in either strain, and hemicholinium-3 did 
not significantly alter the TPR response to 4-AP (data not shown).
The cardiovascular response to nicotine
Stimulation of postganglionic nAchR (Figure  1) with nicotine 
induced a sharp, but transient rise in MBP and TPR in both 
strains (Figure 7). TPR returned to pre-nicotine levels in WKY 
but to below baselines in SHR (P =  0.01). During the initial 
response, there was also a sharp, transient reduction in HR, which 
was statistically significant in SHR only (P = 0.024), reaching its 
nadir level some seconds prior to the MBP/TPR-peak response. 
After a rebound, a slowly developing, sustained bradycardia was 
observed in SHR (P = 0.02), whereas a tachycardia was seen in 
WKY (P = 0.006 after 15 min). Prior administration of 3,4-DAP 
had no effect on the TPR or HR response to nicotine (tested in 
SHR only).
3,4-DaP- and 4-aP-induced salivation
Salivation induced by 3,4-DAP was greater than that after 4-AP. For 
both drugs, salivation was lower in SHR than in WKY (P ≤ 0.004) 
(Table 2). The kallikrein concentration and total amount secreted 
in 3,4-DAP-induced saliva as an indication of sympathetic activa-
tion, was higher in SHR than in WKY, and in both strains the 
total amount secreted was greater than that in 4-AP-induced 
saliva (P ≤ 0.01). Salivation was almost totally eliminated in all 
groups given atropine as part of the pre-treatment (P < 0.001), 
showing that saliva volume depend on parasympathetic activa-
tion. Hexamethonium reduced salivation in WKY, indicating 
involvement of parasympathetic ganglion activation, but did not 
change the kallikrein concentration. In SHR, hemicholinium-3 
and hexamethonium reduced both salivary flow and kallikrein 
secretion, showing involvement of parasympathetic and sympa-
thetic ganglion transmission, respectively. Reserpine had no effect 
FigUre 5 | The TPr and MBP response to 3,4-DaP after pre-treatment with reserpine or nadolol, alone or combined with atropine. The effect of 
nadolol + atropine was not tested in WKY. Significant responses (* within symbol) and group differences (* in brackets) at 1 (left of curves) and 25 min (right of 
curves) were located as indicated. Comparisons were made between the control and the experimental groups, and between the groups pre-treated with reserpine/
atropine and reserpine + atropine, and between the nadolol- and atropine + nadolol-treated groups. *P < 0.025 after curve analyses.
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on 3,4-DAP-induced salivation in either strain, but reduced the 
kallikrein concentration and total amount secreted (P ≤  0.05). 
Still, salivary flow depended also on βAR activation since nadolol 
reduced saliva volume to about 1/3 in WKY and almost totally 
abolished the salivation in SHR (P ≤ 0.008). Quinidine did not 
alter the 3,4-DAP-induced salivation (tested in SHR only, kal-
likrein not measured).
changes in the Plasma catecholamine 
concentrations
In these experiments, re-uptake of NE was not blocked, and the 
changes in the plasma NE concentration were therefore small 
(Table  3). However, the concentration of NE at the end of the 
25-min 3,4-DAP/4-AP-observation period was in both strains 
greater than that in time controls given PBS only (P ≤  0.007) 
and was for both drugs higher in SHR than in WKY (P ≤ 0.008). 
The NE concentration after 4-AP was slightly higher than that 
after 3,4-DAP in WKY (P = 0.005). The plasma concentration of 
epinephrine in the 4-AP and 3,4-DAP controls did not differ from 
that in the time controls.
NE was not detected in plasma from reserpinised WKY (not 
measured in SHR), whereas the concentration of epinephrine 
was not altered. Pre-treatment with nadolol reduced the con-
centration of NE in WKY (P ≤ 0.018) but not in SHR, and had 
no significant effect on the concentration of epinephrine. The 
concentration of both catecholamines was reduced in both strains 
after hemicholinium-3 and hexamethonium, although the differ-
ence was not statistically significant for all. Pre-treatment with 
atropine (measured in SHR only) increased the concentration of 
NE but had no effect on the plasma epinephrine concentration. 
Atropine + nadolol (tested in SHR only) and nadolol did not alter 
the effect of 3,4-DAP on the plasma catecholamine levels.
FigUre 7 | The TPr and hr responses to nicotine, alone and after prior administration of 3,4-DaP. Arrows indicate the injection of nicotine. The 
immediate TPR response was recorded at the peak response, whereas the HR response was recorded at the nadir response, occurring a few seconds earlier. 
*P < 0.025 after curve analyses.
FigUre 6 | The hr response to 4-aP compared to that following 3,4-DaP, and the effect of ach synthesis inhibitor (hemicholinium-3) on the 
response to 4-aP. Arrows indicate the injection of 4-AP or 3.4-DAP. Significant responses (* within symbol) and group differences (* in brackets) at 1 (left of curves) 
and 25 min (right of curves) were located as indicated. *P < 0.025 after curve analyses.
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The concentration of NE in plasma collected 15 min after the 
injection of nicotine was higher than that in the time controls in 
WKY (P = 0.009) but not in SHR, whereas the concentration of 
epinephrine was lower than in the time controls in both strains. 
The concentration of NE but not epinephrine was higher in SHR 
after 3,4-DAP + nicotine than after 3,4-DAP alone.
DiscUssiOn
The main result in the present study was that 3,4-DAP-induced 
inhibition of stabilizing, hyperpolarizing KV currents activated 
Ach release and nAchR signaling in cardiac parasympathetic 
ganglia, and thus precipitated a negative chronotropic effect that 
was blocked by atropine. This response was greater and of longer 
duration in SHR than in WKY. This activated parasympathetic 
component was opposed by the positive chronotropic response 
induced by NE release, activated by inhibition of KV currents, first 
in sympathetic ganglia and subsequently in sympathetic nerve 
endings.
Blockade of hyperpolarizing KV currents with 3,4-DAP 
precipitated transmitter release from postganglionic, parasym-
pathetic, and sympathetic, cardiac nerves. This was demon-
strated by the biphasic HR response to 3,4-DAP, i.e., an initial 
bradycardia followed by tachycardia, eliminated by the mAchR 
TaBle 3 | The concentration of catecholamines in plasma after 4-aP, 3,4-DaP, and nicotine.
groups WKY shr
norepinephrine (nM) epinephrine (nM) norepinephrine (nM) epinephrine (nM)
Time controls (PBS + PBS)a 0.5 ± 0.1   8.1 ± 1.5   1.2 ± 0.2‡ 13.2 ± 2.5
PBS + 4-AP  2.2 ± 0.2* 10.2 ± 2.1    8.3 ± 1.0*,‡   9.5 ± 1.8
PBS + 3,4-DAP   1.4 ± 0.1*† 10.1 ± 1.8    6.0 ± 0.7*,‡ 20.2 ± 4.7
Hemicholinium-3 + 3,4-DAP  0.8 ± 0.2⊦   4.2 ± 2.6   2.7 ± 0.4⊦   5.3 ± 1.4
Hexamethonium + 3,4-DAP Not measured   2.5 ± 0.3⊦    3.4 ± 0.9⊦
Atropine + 3,4-DAP Not measured 12.9 ± 3.1⊦ 18.6 ± 7.8
Reserpine + 3,4-DAP  0.0 ± 0.0⊦   5.5 ± 3.7 Not measured
Reserpine + atropine + 3,4-DAP  0.0 ± 0.0⊦   6.9 ± 1.1 Not measured
Nadolol + 3,4-DAP  0.3 ± 0.3⊦   5.5 ± 0.8 6.8 ± 2.6 14.7 ± 8.9
Atropine + nadolol + 3,4-DAP Not done 9.0 ± 1.8   54.0 ± 15.5
Quinidine + 3,4-DAP Not done   4.1 ± 1.1⊦ 11.4 ± 3.2
Nicotine  2.1 ± 0.3*    3.1 ± 0.7*  1.4 ± 0.3    3.7 ± 2.1*
3,4-DAP + nicotine Not done 12.0 ± 1.3⊦ 26.1 ± 6.0
Significant differences between the time-control and the 4-AP/3,4-DAP/nicotine control groups (*), between the 4-AP and 3,4-DAP control groups within each strain (†), between 
corresponding WKY and SHR PBS/4-AP/3,4-DAP controls (‡ after SHR values), and between corresponding 3,4-DAP control and experimental groups ( ⊦), were detected as 
indicated.
aFrom Ref. (10), run in part intermittently with the present 4-AP and 3,4-DAP control groups. N = 4–9 rats per group, but 20 in the 4-AP-groups.
*,†,‡,⊦P < 0.05.
TaBle 2 | 4-aP- and 3,4-DaP-induced salivation, salivary kallikrein concentration, and total amount kallikrein secreted.
WKY shr
saliva volume (μl) Kallikrein 
concentration (U/ml)
Kallikrein total 
secreted (U)
saliva volume (μl) Kallikrein 
concentration  
(U/ml)
Kallikrein total 
secreted (U)
PBS + 4-AP 39 ± 8 121 ± 40 4 ± 0   12 ± 4* 372 ± 87 17 ± 6
Hemicholinium-3 + 4-AP  75 ± 30 14 ± 5 1 ± 0    1 ± 1 Not measured
PBS + 3,4-DAP   620 ± 102†  50 ± 15 27 ± 5†    230 ± 38*†  1096 ± 427*     380 ± 151*†
Hemicholinium-3 + 3,4-DAP 561 ± 35 Not measured     93 ± 21‡  14 ± 9‡    2 ± 2‡
Hexamethonium + 3,4-DAP 343 ± 47‡ 34 ± 8 10 ± 1‡  114 ± 52  142 ± 31‡    36 ± 11‡
Atropine + 3,4-DAP 49 ± 6‡ 91 ± 9‡  4 ± 2‡   17 ± 7‡ Not measured
Reserpine + 3,4-DAP 590 ± 77 20 ± 3‡ 12 ± 2‡ 234 ± 4    42 ± 10‡    9 ± 3‡
Reserpine + atropine + 3,4-DAP   24 ± 10‡ Not measured     0 ± 0‡ Not measured
Nadolol + 3,4-DAP 307 ± 83‡ Not measured     17 ± 10‡ Not measured
Atropine + nadolol + 3,4-DAP Not done     7 ± 4‡ Not measured
Quinidine + 3,4-DAP Not done  335 ± 79 Not measured
Saliva was collected from the oral cavity throughout the 25-min observation period. Significant differences between the WKY and SHR 4-AP/3,4-DAP control groups (*), between 
corresponding 4-AP and 3,4-DAP control groups (†), and between corresponding control and experimental groups (‡), were detected as indicated.
*,†,‡P < 0.05.
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antagonist atropine and the sympatholytic agent reserpine, 
respectively (Figure  1). The parasympathetic bradycardia 
involved activation of parasympathetic ganglion transmission, 
with Ach release from preganglionic neurons and subsequent 
activation of nAchR in the postganglionic neuron. This was 
concluded since the 3,4-DAP-induced bradycardia was also 
eliminated by the Ach synthesis inhibitor hemicholinium-3 
and the nAchR antagonist hexamethonium (Figure 1). When 
the influence of this parasympathetic activation was inhibited 
by atropine, which does not block ganglion transmission, the 
initial bradycardia was replaced by tachycardia. Thus, 3,4-DAP 
in addition activated sympathetic ganglion transmission that 
elicited a positive chronotropic component. This conclusion was 
further confirmed by that 3,4-DAP induced neither bradycardia 
nor tachycardia after pre-treatment with reserpine combined 
with atropine. Compatible with a counter-acting effect of the 
simultaneous parasympathetic and sympathetic activation, 
reserpine enhanced the initial, 3,4-DAP-induced bradycardia 
in SHR.
The late 3,4-DAP-induced tachycardia appeared to involve 
some activation of sympathetic ganglion transmission in WKY, 
since ΔHR at the end of the 3,4-DAP-observation period was 
lowered by hexamethonium. However, this was not the case 
in SHR, where the late reserpine-sensitive tachycardia, unlike 
the initial response, was not reduced by hemicholinium-3 or 
hexamethonium. The late tachycardia was therefore in this strain 
precipitated exclusively by NE release due to inhibition of KV in 
the postganglionic sympathetic nerve terminals.
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Since 3,4-DAP is a KV blocker, the parasympathetic compo-
nent activated by 3,4-DAP demonstrated the impact of inhibi-
tory, hyperpolarizing KV currents on parasympathetic ganglion 
Ach release (Figure 1). The role of these KV currents was far more 
pronounced in SHR than in WKY. This was clearly demonstrated 
by the strongly increased bradycardia during both the initial and 
the late HR response to 3,4-DAP in SHR when the sympathetic 
influence had been eliminated by reserpine. In addition, removal 
of this parasympathetic component by hemicholinium-3, 
hexamethonium, or atropine enhanced the 3,4-DAP-induced 
tachycardia in the interval between 10 and 20 min in SHR but 
not in WKY. Thus, the inhibitory effect of 3,4-DAP-induced 
parasympathetic ganglion activation on the positive chrono-
tropic response to NE release was sustained in SHR, different 
from the transient effect in WKY, demonstrating enhanced KV 
inhibition of ganglion transmission in SHR. Augmented KV cur-
rents in the preganglionic nerve terminal will stabilize the neuron 
and hamper parasympathetic ganglion transmission (Figure 1), 
thus functioning as a bottleneck to parasympathetic ganglion 
transmission, similar to that described for parasympathetic 
ganglia in myocardial infarction (8). The resulting parasym-
pathetic hypoactivity will therefore cause HR to be controlled 
predominantly by the adrenergic component, compatible with 
that observed in SHR and hypertensive patients (1–3). The car-
diac parasympathetic ganglia are located in clusters in fat tissue 
in the atrial epicardium and in the atrial and ventricular septa 
[reviewed in Ref. (28)], where they control vagal trafficking to 
the heart. Electrical stimulation of the sinoatrial-innervating 
ganglion elicited bradycardia, whereas the atrioventricular-
innervating ganglion did not (29). The enhanced KV inhibition 
of parasympathetic ganglion transmission in SHR may therefore 
reside within sinoatrial-innervating ganglion cells.
The peripherally restricted β1+2AR antagonist nadolol 
eliminated the 3,4-DAP-induced tachycardia in both strains, 
compatible with the fact that the tachycardia depended on 
3,4-DAP-induced NE release, as demonstrated by reserpine. 
However, different from that after reserpine, pre-treatment 
with nadolol did not precipitate a sustained 3,4-DAP-induced 
bradycardia. This difference was most likely explained by the 
fact that the negative chronotropic effect of vagal stimulation is 
largely dependent on the presence of sympathetic activity (9). 
Blockade of the cardiac βAR therefore eliminated the substrate 
for the parasympathetic influence. This differed from that after 
reserpine, where circulating epinephrine apparently maintained 
βAR activation. However, nadolol had no effect on the initial, 
atropine-sensitive 3,4-DAP-induced bradycardia, which may be 
explained by the more slowly developing sympathetic activation, 
thus allowing the parasympathetic activation to dominate the 
HR response in this early phase. The conditions, which elicit the 
elevated KV inhibition of parasympathetic ganglion transmission 
in SHR, may therefore preferably be studied in reserpinized rats, 
where its influence on HR control is easily detectable.
An effect of 3,4-DAP on Ach release from the preganglionic 
parasympathetic neuron, with subsequent stimulation of postsyn-
aptic nAchR in the postganglionic neuron, was supported by the 
fact that 3,4-DAP did not influence the HR response to nicotine 
in SHR. However, the HR response to nicotine differed in the two 
strains, with an acute bradycardia, which, after a rebound, was 
followed by a sustained bradycardia in SHR, but by tachycardia 
in WKY. The bradycardia in SHR was likely to result from an 
increased number and/or sensitivity of the nAchR in order to 
compensate for the KV-dependent reduction in Ach release from 
the parasympathetic preganglionic neuron (Figure 1). A similar 
argument may also explain the late reduction in TPR following 
nicotine in SHR. The slowly developing, transient tachycardia 
seen in WKY may involve presynaptic nAchR, which enhanced 
sympathetic nerve NE release (30), in agreement with the slightly 
elevated NE overflow after nicotine in this strain. The elevated 
NE concentration in plasma from SHR given 3,4-DAP + nicotine 
compared to 3,4-DAP alone was likely to result from similar 
mechanisms or from the prolonged action of 3,4-DAP in the 
former group.
Presynaptic nAchR also appeared to enhance the 3,4-DAP-
induced release of NE since both hemicholinium-3 and hexam-
ethonium but not atropine reduced the plasma concentration of 
NE in both strains (Figure 1). NE overflow was also reduced by 
nadolol in WKY, in agreement with the fact that both β1AR and 
β2AR may facilitate NE release (31).
Ach release and activation of nAchR also control catecho-
lamine secretion from adrenal chromaffin cells. The secre-
tion of epinephrine was activated by surgical stress, since the 
plasma epinephrine concentration was almost totally absent 
in plasma from rats not subjected to surgery (32), and the 
concentration after 3,4-DAP was not different from that in the 
time controls. This secretion evidently involved activation of 
adrenal nAchR, since both hemicholinium-3 and hexametho-
nium but not atropine reduced the plasma concentration of 
epinephrine.
3,4-DAP and 4-AP are non-selective KV blockers, and the 
response to 4-AP was not influenced by inhibitors of several 
non-KV K+ channels (10). On the other hand, 3,4-DAP will influ-
ence KV channels also in other cells, such as cardiac pacemaker 
cells and cardiomyocytes, where KV contribute to action potential 
repolarization. However, inhibition of such currents apparently 
had little impact on the HR response to 3,4-DAP, since no HR 
response and only a minor tachycardia was observed in WKY and 
SHR, respectively, after pre-treatment with reserpine + atropine. 
The HR response to 3,4-DAP was therefore fully explained by 
its effect on the two branches of the autonomic nervous system.
The initial 3,4-DAP-activated bradycardia was not likely to 
result from baroreceptor activation due to the simultaneous rise 
in BP, since a similar rise in BP following selective stimulation 
of NE release by tyramine, precipitated tachycardia only (19), 
even when analyzed at high-resolution intervals within the first 
minute (Berg, unpublished observations). We have previously 
demonstrated that baroreflex control of HR was eliminated in 
Nembutal anesthetized rats, as large changes in BP elicited hardly 
any change in HR (33, 34). Furthermore, the present results 
demonstrated that when the late elevated TPR and BP in SHR 
was eliminated by reserpine, 3,4-DAP still induced bradycardia in 
this interval, thus excluding a role of baroreceptor activation. The 
absence of bradycardia during tyramine-induced increase in TPR 
and the augmented bradycardia in reserpinized SHR where the 
TPR response to 3,4-DAP was eliminated, also indicated that the 
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3,4-DAP-induced bradycardia did not result from failing cardiac 
function due to cardiac vasoconstriction.
The antiarrhythmic drug quinidine reduced BP and HR base-
lines in SHR. These actions may possibly result from enhanced 
vagal transmission due to KV 1.5 inhibition, parallel to that dem-
onstrated for VSMC KV 1.5 (22, 23). The effect of quinidine on the 
HR response to 3,4-DAP mimicked that of atropine, compatible 
with the known anti-mAchR effect of this drug (24). However, 
unlike atropine, the 3,4-DAP-induced tachycardia remained 
elevated also after 25 min after pre-treatment with quinidine. If 
the KV responsible for 3,4-DAP parasympathetic ganglion activa-
tion, in fact, included KV 1.5, this observation may possibly result 
from an increased dose of KV 1.5 inhibitor.
3,4-Diaminopyridine-induced salivary flow appeared to be a 
pure parasympathetic response, since it was almost totally abol-
ished by atropine but was not influenced by reserpine. However, it 
was also reduced in WKY and abolished in SHR by nadolol, indi-
cating that salivation depended on a permissive βAR influence. 
The mechanisms responsible for this βAR influence were not clear. 
The 3,4-DAP-induced salivation was in both strains about 20 
times greater than that induced by 4-AP, indicating that 3,4-DAP 
was a more efficient activator of Ach release than 4-AP. Salivation 
in response to 3,4-DAP was greater in WKY than in SHR. The role 
of parasympathetic ganglion and/or neuronal Ach release was not 
clear cut, but seemed in both strains to involve both levels, as 
indicated by the effect of hemicholinium-3, hexamethonium, or 
atropine. These results paralleled the augmented effect of 3,4-DAP 
on cardiac parasympathetic ganglion transmission compared to 
4-AP, although in the heart with a greater effect in SHR than in 
WKY. This drug-dependent difference in the cardiac response 
was clearly demonstrated in reserpinised SHR, where 3,4-DAP 
induced a prominent bradycardia (present study) whereas 4-AP 
did not (10). Also, the secretion of kallikrein, which is primarily 
activated by α1AR stimulation of submandibular gland granular 
tubules (25), was greater after 3,4-DAP than 4-AP, and much 
greater in SHR than in WKY. The secretion of kallikrein in SHR 
involved activation of sympathetic ganglion transmission, since it 
was reduced after hemicholinium-3, hexamethonium, and reser-
pine. It therefore seemed that 3,4-DAP-activated sympathetic 
as well as parasympathetic ganglion transmission in the heart 
as well as in other organs as demonstrated here for the salivary 
glands, and with a variable strain-related difference for different 
functions.
4-aminopyridine, unlike 3,4-DAP, readily enters CNS where 
it stimulates sympathetic output (11–13, 15). The difference in 
transport across the blood–brain barrier was clearly evident 
by the muscular twitches due to CNS cortical stimulation, 
observed in response to 4-AP but not 3,4-DAP (15). However, 
the 4-AP-activated sympathetic control of HR did not differ 
from that induced by 3,4-DAP, since a drug-related difference 
was no longer detected when the augmented parasympathetic 
influence in SHR had subsided, i.e., after 25 min. This observa-
tion paralleled the similar plasma NE overflow following 4-AP 
and 3,4-DAP.
3,4-Diaminopyridine, like previously demonstrated for 4-AP 
(10, 14, 15), induced an immediate rise in TPR, transient in WKY, 
but sustained in SHR. The TPR-peak response to 3,4-DAP was in 
part reduced by reserpine in WKY and by reserpine + atropine 
in SHR. The vasoconstriction was therefore likely to result from 
inhibition of hyperpolarizing, relaxing VSMC KV as well as from 
the 3,4-DAP-induced NE release, particularly in WKY. The K+ 
channels mainly found in arterial VSMC are KV1.2 and 1.5 and 
the high conductance, Ca2+-gated K+ channel (BKCa), with BKCa 
playing a greater role than KV in hypertension [for review, see 
in Ref. (35)]. A clear strain-related difference was not detected 
in the initial TPR response to 3,4-DAP (present study) or to 
4-AP (10). However, the TPR response to 4-AP was increased 
after inhibition of protein kinase C (PKC) or inhibition of the 
PKC-generating α1AR, and angiotensin AT1 and endothelin A 
receptors (14), in accordance with an inhibitory effect of PKC on 
VSMC KV (36). Excessive activation of PKC in SHR may therefore 
shift the balance from KV to BKCa control of vascular tension. 
Interestingly, exercise increased KV1.2 and KV1.5- and decreased 
BKCa-expression in SHR, paralleled by a reduction in BP (37). A 
shift from KV to a BKCa control of vascular tension in SHR may 
explain why quinidine did not increase TPR baseline or the TPR 
response to 3,4-DAP in SHR (not tested in WKY). The reason for 
the increased immediate ΔTPR after hemicholinium-3 in SHR, 
with a similar tendency also after atropine, may possibly suggest 
an increase in KV currents after parasympathetic inhibition in 
this strain. The elevated TPR response during the late part of the 
response to 3,4-DAP in SHR was, as that in response to 4-AP 
(10), eliminated by reserpine, showing that it resulted from the 
release of NE.
The SHR is also an animal model for attention deficit hyper-
activity disorder (ADHD). However, the present results were 
performed on anesthetized rats. In addition, ADHD results from 
changes in the CNS, whereas 3,4-DAP does not cross the blood–
brain barrier and has a peripheral action exclusively. It therefore 
did not seem likely that this comorbidity directly influenced the 
present results.
cOnclUsiOn
The present study showed that blocking KV with 3,4-DAP induced 
Ach release in cardiac parasympathetic ganglia with a far greater 
and more sustained effect on HR in SHR than in WKY. It could 
therefore be deduced that parasympathetic ganglion transmission 
was inhibited in this strain by an augmented hyperpolarizing KV 
current, which stabilized the neurons and prevented presynaptic 
Ach release and activation of the postsynaptic ganglion nAchR. 
This enhanced KV activity was therefore likely to preclude the 
protective effect of vagal function, as it has been observed in 
hypertension and also congestive heart failure (38, 39). A result-
ing cardiac sympathetic hyperactivity may lead to hypertensive 
left ventricular hypertrophy (40), an independent predictor of 
morbidity and mortality (41). The mechanism underlying the 
augmented parasympathetic ganglion KV currents and, thus, 
vagal dysfunction in SHR is as yet not known.
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